A large variety of cardiotoxic events with manifestations such as myocarditis, heart failure, cardiomyopathy, heart block, and myocardial fibrosis were documented in PD-1 blocking immunotherapy (Liu et al., 2022). Here, PDCD1 is linked to cardiomyopathy.